Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Oncolytics Biotech Inc. (ONCY) had Return on Tangible Equity of 757.02% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-28.76M |
|
-- |
|
-- |
|
$28.73M |
|
$-28.73M |
|
$0.04M |
|
$-28.68M |
|
$-28.68M |
|
$-28.76M |
|
$-28.76M |
|
$-28.76M |
|
$-28.76M |
|
$-28.73M |
|
$-28.66M |
|
95.86M |
|
95.86M |
|
$-0.30 |
|
$-0.30 |
|
| Balance Sheet Financials | |
$6.84M |
|
$0.23M |
|
$0.74M |
|
$7.58M |
|
$6.10M |
|
-- |
|
$5.28M |
|
$11.38M |
|
$-3.80M |
|
$-3.80M |
|
$-3.80M |
|
108.02M |
|
| Cash Flow Statement Financials | |
$-20.11M |
|
$-0.01M |
|
$14.12M |
|
$11.08M |
|
$5.20M |
|
$-5.88M |
|
$3.10M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.12 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-20.12M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
757.02% |
|
|
Return on Tangible Equity |
757.02% |
-379.31% |
|
757.01% |
|
$-0.04 |
|
$-0.21 |
|
$-0.21 |
|